Pulling SEC filings + quote and writing the call…

TREACE MEDICAL CONCEPTS, INC.
Next earnings Aug 5, 2026 (after close) · consensus $-0.30 EPS, $44.9M rev
Last earnings +4.7% on 2026-05-08
Unprofitable (net margin -27.7%).
TREACE MEDICAL CONCEPTS, INC. shows $213M in FY2025 revenue (+1.6% YoY), a -27.7% net margin, and -67.6% ROE.
Sources: SEC EDGAR (CIK 0001630627, latest 10-Q filed 2026-05-08) · EODHD · as of 6/26/2026, 12:45:13 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $94.4M | $142M | $187M | $209M | $213M |
| Gross profit | $77.5M | $116M | $152M | $168M | $170M |
| Operating income | -$16.5M | -$34.8M | -$51.4M | -$55.7M | -$54.2M |
| Net income | -$20.6M | -$42.8M | -$49.5M | -$55.7M | -$59.0M |
| Diluted EPS | -$0.43 | -$0.77 | -$0.81 | -$0.90 | -$0.93 |
| Net margin | -21.8% | -30.2% | -26.5% | -26.6% | -27.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1047 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Last 90 days: 6 open-market buys · 0 sales
| 2026-06-11 | Treace John T. Chief Executive Officer | Buy | 22.9K @ $4.04 | $92.5K |
| 2026-06-10 | Treace John T. Chief Executive Officer | Buy | 29.4K @ $4.02 | $118K |
| 2026-06-01 | Treace John T. Chief Executive Officer | Buy | 50.0K @ $3.56 | $178K |
| 2026-05-28 | Treace John T. Chief Executive Officer | Buy | 61.2K @ $3.02 | $185K |
| 2026-05-27 | Treace John T. Chief Executive Officer | Buy | 49.8K @ $2.87 | $143K |
| 2026-05-26 | Treace John T. Chief Executive Officer | Buy | 4.51K @ $2.79 | $12.6K |
| 2026-05-19 | BAKEWELL JOHN K Director | Award | 30.0K | |
| 2026-05-19 | Kiernan Jane E Director | Award | 30.0K | |
| 2026-05-19 | Berry Lance A Director | Award | 30.0K | |
| 2026-05-19 | Jain Deepti Director | Award | 30.0K | |
| 2026-05-19 | HAMILTON LAWRENCE W Director | Award | 30.0K |